Cyclacel Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Cyclacel Pharmaceuticals's estimated annual revenue is currently $3.5M per year.
- Cyclacel Pharmaceuticals's estimated revenue per employee is $233,333
- Cyclacel Pharmaceuticals's total funding is $166.7M.
Employee Data
- Cyclacel Pharmaceuticals has 15 Employees.
- Cyclacel Pharmaceuticals grew their employee count by -12% last year.
Cyclacel Pharmaceuticals's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Chief Medical Officer | Reveal Email/Phone |
2 | EVP, CFO & COO | Reveal Email/Phone |
3 | Head Clinical Operations | Reveal Email/Phone |
4 | Head Research | Reveal Email/Phone |
5 | Associate Director, Clinical Data Management | Reveal Email/Phone |
6 | Interim Chief Medical Officer | Reveal Email/Phone |
7 | SVP & Chief Medical Officer | Reveal Email/Phone |
8 | Group Management Accountant | Reveal Email/Phone |
9 | President & CEO | Reveal Email/Phone |
10 | Senior Director, Business Development and Project Management | Reveal Email/Phone |
Cyclacel Pharmaceuticals Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5M | 25 | -11% | N/A | N/A |
#2 | $35.8M | 178 | 8% | N/A | N/A |
#3 | $5.4M | 27 | -25% | N/A | N/A |
#4 | $4180M | 14516 | 1% | $550M | N/A |
#5 | $12.5M | 62 | 15% | N/A | N/A |
#6 | $6.7M | 119 | -37% | $199.6M | N/A |
#7 | $9.4M | 47 | 7% | N/A | N/A |
#8 | $10.3M | 51 | 6% | N/A | N/A |
#9 | $106.3M | 529 | 16% | N/A | N/A |
#10 | $15.5M | 77 | 20% | N/A | N/A |
What Is Cyclacel Pharmaceuticals?
Cyclacel is a biopharmaceutical company dedicated to the discovery, development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. Cyclacel's discovery engines integrate cell cycle biology expertise with a large library of gene-based targets, RNAi functional genomics, chemogenomics and clinical biomarker technologies to deliver new drugs. The company is currently evaluating seliciclib (CYC202), an orally-available Cyclin Dependent Kinase inhibitor, in Phase II clinical trials for the treatment of non-small cell lung cancer and B-cell hematological malignancies. CYC682 is an orally-available, cell cycle modulating nucleoside analog in Phase I clinical trials for the treatment of cancer. Cyclacel has eight additional programs at preclinical stages. Cyclacel has entered into corporate alliances with Altana, AstraZeneca, CV Therapeutics, GlaxoSmithKline, Lorus and Sankyo all in the oncology field. Cyclacel is the first European university spin-out company to have raised more than $100 million in private equity.
keywords:N/A
$166.7M
Total Funding
15
Number of Employees
$3.5M
Revenue (est)
-12%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Cyclacel Pharmaceuticals News
Cyclacel Pharmaceuticals, Inc is a clinical stage biopharmaceutical company. It uses cell cycle, transcriptional regulation and DNA damage...
About Cyclacel Pharmaceuticals, Inc. Cyclacel is a clinical-stage, biopharmaceutical company developing innovative cancer medicines based on...
Cyclacel is a clinical-stage, biopharmaceutical company developing innovative cancer medicines based on cell cycle, transcriptional regulation...
BERKELEY HEIGHTS, N.J., Nov. 05, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced dosing of the first patient in the Company’s mu ...
Next-Generation CDK2/9 Inhibitor Fadraciclib to Be Evaluated as a Single Agent and in Combinations in Streamlined, Registration-Directed Study BERKELEY HEIGHTS, N.J., Nov. 05, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a b ...
Other Companies in Berkeley Heights
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $4.6M | 20 | -5% | N/A |
#2 | $3.3M | 23 | 0% | N/A |
#3 | $15M | 26 | 13% | $22.5M |
#4 | $5.8M | 29 | 7% | N/A |
#5 | $6.5M | 34 | 3% | N/A |